Scholar Rock Holding Corporation - Common Stock (NQ:SRRK)

46.09 UNCHANGED

Delayed Quote Updated: 4:00 PM EST, Nov 4, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Scholar Rock Holding Corporation - Common Stock

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Stocks That Hit 52-Week Lows On Thursday ↗

April 21, 2022

On Thursday, 236 companies hit new 52-week lows.

Via Benzinga

Scholar Rock Presents Data Analysis of Multiple Efficacy Endpoints from the Apitegromab TOPAZ Phase 2 Trial at the 2022 European Paediatric Neurology Society Congress

April 21, 2022

From Scholar Rock

Via Business Wire

The Daily Biotech Pulse: BioXcel's Igalmi Gets FDA Nod, Citius Spikes On Positive Phase 3 Data, Iovance Receives Positive Regulatory Feedback For Skin Cancer Therapy ↗

April 06, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours.

Via Benzinga

The Week Ahead In Biotech (April 3-April 9): BioXcel FDA Decision, Neurology Conference Presentations Take The Spotlight ↗

April 03, 2022

Biopharma stocks outperformed the broader market in the week ending April 2, thereby recouping the losses from the previous week. Clinical readouts and FDA decisions were among the chief catalysts that...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For March 23, 2022 ↗

March 23, 2022

Upgrades For E2open Parent Holdings Inc (NYSE:ETWO), Colliers Securities upgraded the previous rating of Neutral to Buy. At the moment, the stock has a 52-week-high of $14.58 and...

Via Benzinga

Scholar Rock Presents Data Analysis of Multiple Efficacy Endpoints from the Apitegromab TOPAZ Phase 2 Trial at the American Academy of Neurology 2022 Annual Meeting

March 22, 2022

From Scholar Rock

Via Business Wire

Scholar Rock To Highlight Apitegromab Data From Ambulatory Cohort In Muscular Dystrophy ↗

March 14, 2022

Scholar Rock Holding Corp (NASDAQ: SRRK) will showcase data from an exploratory analysis of the ambulatory cohort in the Phase 2 TOPAZ trial of apitegromab in individuals...

Via Benzinga

Stocks That Hit 52-Week Lows On Wednesday ↗

March 16, 2022

On Wednesday, 90 companies set new 52-week lows. Areas of Significance In Today's 52-Week Lows: The company with the largest market cap to set a new 52-week low was...

Via Benzinga

Stocks That Hit 52-Week Lows On Monday ↗

March 14, 2022

On Monday, 671 companies achieved new lows for the year. Points of Interest From Today's 52-Week Lows: Alibaba Group Holding (NYSE:BABA) was the largest firm by...

Via Benzinga

Scholar Rock to Present Data from TOPAZ Ambulatory Cohort Analysis at the 2022 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

March 13, 2022

From Scholar Rock

Via Business Wire

Scholar Rock to Present at Cowen’s 42nd Annual Health Care Conference

February 25, 2022

From Scholar Rock

Via Business Wire

Scholar Rock to Present Biomarker Strategy for SRK-181 at the TGFβ for Immuno-Oncology Drug Development Summit

January 25, 2022

From Scholar Rock

Via Business Wire

Stocks That Hit 52-Week Lows On Friday ↗

January 14, 2022

During Friday's session, 445 companies made new 52-week lows. Noteable 52-Week Lows: Intuitive Surgical (NASDAQ:ISRG) is the largest company in terms of market cap to...

Via Benzinga

Scholar Rock Provides Corporate Update and Highlights Priorities for 2022

January 10, 2022

From Scholar Rock

Via Business Wire

Scholar Rock to Present at the 40th Annual J.P. Morgan Healthcare Conference

January 04, 2022

From Scholar Rock

Via Business Wire

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

December 22, 2021

Gainers BiondVax Pharmaceuticals (NASDAQ:BVXV...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For December 22, 2021 ↗

December 22, 2021

Upgrades According to Loop Capital, the prior rating for Williams-Sonoma Inc (NYSE:

Via Benzinga

Scholar Rock Outlines Pivotal Apitegromab Trial Design In Spinal Muscular Atrophy Patients ↗

December 01, 2021

Scholar Rock Holding Corp (NASDAQ: SRRK) announced the study design for the SAPPHIRE Phase 3 trial of apitegromab, a selective inhibitor of the activation of latent...

Via Benzinga

Scholar Rock Announces Design of Phase 3 SAPPHIRE Clinical Trial Evaluating Apitegromab in Non-Ambulatory Patients with Type 2 and Type 3 Spinal Muscular Atrophy (SMA)

November 30, 2021

From Scholar Rock

Via Business Wire

Scholar Rock Presents Data from Part A of the DRAGON Phase 1 Trial Evaluating SRK-181 as Monotherapy and in Combination with Anti-PD-(L)1 for the Treatment of Solid Tumors -- Announces Advancement into Part B

November 12, 2021

From Scholar Rock

Via Business Wire

48 Stocks Moving In Friday's Mid-Day Session ↗

November 26, 2021

Gainers Allied Healthcare Products, Inc. (NASDAQ: AHPI) shares jumped 68% to $9.04. Shares of mask and protective apparel companies, including Allied Healthcare Products, traded...

Via Benzinga

Scholar Rock Reports Third Quarter 2021 Financial Results and Highlights Business Progress

November 09, 2021

From Scholar Rock

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For November 19, 2021 ↗

November 19, 2021

Upgrades Morgan Stanley upgraded the previous rating for EQT Corp (NYSE:

Via Benzinga

Scholar Rock to Present at Upcoming Healthcare Conferences

November 02, 2021

From Scholar Rock

Via Business Wire

Scholar Rock to Present Apitegromab TOPAZ Phase 2 Pharmacologic Data at the 2021 World Congress of Neurology

October 03, 2021

From Scholar Rock

Via Business Wire

Scholar Rock Presents Exploratory Responder Analysis on Efficacy Data from the Apitegromab TOPAZ Phase 2 Trial at the Child Neurology Society Annual Meeting

September 30, 2021

From Scholar Rock

Via Business Wire

The Daily Biotech Pulse: AbbVie's Migraine Drug OK'd By FDA, Amicus Spins Off Gene Therapy Business, Geovax In-Licenses Cancer Drug ↗

September 29, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Click here for accessing Benzinga's FDA Calendar Scaling The Peaks (Biotech Stocks...

Via Benzinga

Scholar Rock Announces Issuance of U.S. Patent Protecting SRK-181, an Inhibitor of TGFβ1 Activation

September 28, 2021

From Scholar Rock

Via Business Wire

Scholar Rock Presents Additional Data Analyses from the Apitegromab TOPAZ Phase 2 Trial at the World Muscle Society 2021 Virtual Congress

September 23, 2021

From Scholar Rock

Via Business Wire

Scholar Rock to Present at the 2021 Cantor Virtual Global Healthcare Conference

September 22, 2021

From Scholar Rock

Via Business Wire

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.